Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries

Orphanet Journal of Rare Diseases

Volumn 11, Issue 1, 2016, Pages

  Zelei, Tamás ^a   Molnár, Mária J ^b   Szegedi, Márta ^b   Kaló, Zoltán ^a,c  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Syreon Research Institute   (Hungary)

Author keywords

Central and Eastern Europe; Cost effectiveness; Drug approval; Economic evaluation; Orphan drug; Rare disease; Technology assessment

Indexed keywords

ORPHAN DRUG;

BUDGET; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG EFFICACY; EUROPE; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; REIMBURSEMENT; REVIEW; SYSTEMATIC REVIEW; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; DRUG MANUFACTURE; ECONOMICS; PROCEDURES; RARE DISEASES;

COST-BENEFIT ANALYSIS; DRUG COSTS; EUROPE; HUMANS; ORPHAN DRUG PRODUCTION; RARE DISEASES; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84971597199     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-016-0455-6     Document Type: Review

References (98)

1. Orphan Designation. European Medicines Agency, London. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general-content-000029.jsp&mid=WC0b01ac05800240ce. Accessed 26 October 2015.
2. Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010-2020. Orphanet J Rare Dis. 2011;6:62. doi: 10.1186/1750-1172-6-62.
3. Register of designated Orphan Medicinal Products. European Commission. Directorate General Health and Food Safety. http://ec.europa.eu/health/documents/community-register/html/orphreg.htm. Accessed 5 October 2015.
4. Orphan medicines designation (COMP). EURORDIS, Paris. www.eurordis.org/content/orphan-drug-designation. Accessed 5 October 2015.
5. List of orphan drugs with marketing authorizations. Orphanet Portal. http://www.orpha.net/consor/cgi-bin/Drugs-ListOrphanDrugs.php?lng=EN. Accessed 5 October 2015.
6. How to Apply for Designation as an Orphan Product (Orphan Drug Act). Food and Drug Administration, HHS. 1992. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/ucm135122.htm. Accessed 5 October 2015.
7. REGULATION (EC) No 141/2000 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 1999 on orphan medicinal products. Europena Parliament and the Council. 2000. http://ec.europa.eu/health/files/eudralex/vol-1/reg-2000-141/reg-2000-141-en.pdf. Accessed 26 October 2015.
8. McCabe C. Balancing economic, ethical and equity concerns in orphan drugs and rare diseases. EJHP Practice. 2010;16(4):22-5.
9. Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the Orphan Drug System: Break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis. 2012;7:74. doi: 10.1186/1750-1172-7-74.
10. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-9. w64.
11. Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria. Health Policy. 2012;108(1):10-8.
12. Iskrov GG, Raycheva RD, Stefanov RS. Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs. Folia Med. 2013;55(3-4):80-6.
13. Logviss K, Krievins D, Purvina S. Rare diseases and orphan drugs: Latvian story. Orphanet J Rare Dis. 2014;9(1):147. doi: 10.1186/s13023-014-0147-z.
14. Pavlović N, Stanimirov B, Stojančević M, Paut-Kusturica M, Stoimenova A, Goločorbin-Kon S, et al. An insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and Sweden. Biotechnol Biotechnol Equip. 2012;26(5):3236-41.
15. Picavet E, Annemans L, Cleemput I, Cassiman D, Simoens S. Market uptake of orphan drugs - A European analysis. J Clin Pharm Ther. 2012;37(6):664-7.
16. Sasinowski F. Quantum of effectiveness evidence in FDA's approval of orphan drugs. Drug Inf J. 2012;46:238-63.
17. Côté A, Keating B. What is wrong with orphan drug policies? Value Health. 2012;15(8):1185-91.
18. Kalo Z, Landa K, Dolezal T, Voko Z. Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. Eur J Cancer Care. 2012;21(4):442-9. doi: 10.1111/j.1365-2354.2012.01351.x.
19. Dear JW, Lilitkarntakul P, Webb DJ. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. Br J Clin Pharmacol. 2006;62(3):264-71. doi: 10.1111/j.1365-2125.2006.02654.x.
20. Kanters TA, de Sonneville-Koedoot C, Redekop WK, Hakkaart L. Systematic review of available evidence on 11 high-priced inpatient orphan drugs. Orphanet J Rare Dis. 2013;8:124. doi: 10.1186/1750-1172-8-124.
21. Facey K, Granados A, Guyatt G, Kent A, Shah N, van der Wilt GJ, et al. Generating health technology assessment evidence for rare diseases. Int J Technol Assess Health Care. 2014;30(4):416-22. doi: 10.1017/s0266462314000464.
22. Kesselheim AS, Gagne JJ. Strategies for postmarketing surveillance of drugs for rare diseases. Clin Pharmacol Ther. 2014;95(3):265-8.
23. Foltánová T, Mazág M. Orphan dugs in EU. Acta Facultatis Pharmaceuticae Universitatis Comenianae. 2013;60(SUPPL. 8):26-31.
24. Clarke JT. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. CMAJ. 2006;174(2):189-90. doi: 10.1503/cmaj.050706.
25. Winquist E, Bell CM, Clarke JTR, Evans G, Martin J, Sabharwal M, et al. An evaluation framework for funding drugs for rare diseases. Value Health. 2012;15(6):982-6.
26. Laupacis A. Evidence and values: requirements for public reimbursement of drugs for rare diseases - A case study in oncology. Can J Clin Pharmacol. 2009;16(2):e282-e94.
27. Hyde R, Dobrovolny D. Orphan drug pricing and payer management in the United States: are we approaching the tipping point? Am Health Drug Benefits. 2010;3(1):15-22.
28. Rosenberg-Yunger ZRS, Daar AS, Thorsteinsdóttir H, Martin DK. Priority setting for orphan drugs: an international comparison. Health Policy. 2011;100(1):25-34.
29. Paulden M, Stafinski T, Menon D, McCabe C. Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. Pharmacoeconomics. 2015;33(3):255-69. doi: 10.1007/s40273-014-0235-x.
30. Sussex J, Rollet P, Garau M, Schmitt C, Kent A, Hutchings A. A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health. 2013;16(8):1163-9.
31. Panju AH, Bell CM. Policy alternatives for treatments for rare diseases. CMAJ. 2010;182(17):E787-E92.
32. Dupont AG, Van Wilder PB. Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol. 2011;71(4):488-96.
33. Tordrup D, Tzouma V, Kanavos P. Orphan drug considerations in Health Technology Assessment in eight European countries. Rare Dis Orphan Drugs. 2014;1(3):86-97.
34. Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: Do they deserve special status for funding? QJM. 2005;98(11):829-36.
35. Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42. doi: 10.1186/1750-1172-6-42.
36. Simoens S, Picavet E, Dooms M, Cassiman D, Morel T. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy. 2013;11(1):1-3.
37. Drummond M, Evans B, LeLorier J, Karakiewicz P, Martin D, Tugwell P, et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases - A case study in oncology. Can J Clin Pharmacol. 2009;16(2):e273-e81.
38. Drummond M, Towse A. Orphan drugs policies: a suitable case for treatment. Eur J Health Econ. 2014;15(4):335-40.
39. Kanavos P, Nicod E. What is wrong with orphan drug policies? Suggestions for ways forward. Value Health. 2012;15(8):1182-4.
40. Sheldon T. Dutch doctors call for EU evaluation of cost effectiveness of high cost orphan drugs. BMJ. 2012;345:e5461. doi: 10.1136/bmj.e5461.
41. Zitter M. Managing drugs for rare genetic diseases: trends and insights. Manag Care. 2005;14(2):52-4, 7-5460, 63-64; quiz 66-67.
42. Drummond MF, Wilson DA, Kanavos P, Ubel PA, Rovira J. Assessing the economic challenges posed by orphan drugs: a response to McCabe et al. [2]. Int J Technol Assess Health Care. 2007;23(3):401-4.
43. McCabe C, Tsuchiya A, Claxton K, Raftery J. Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al. [1]. Int J Technol Assess Health Care. 2007;23(3):397-401.
44. McCabe C, Edlin R, Round J. Economic considerations in the provision of treatments for rare diseases. Adv Exp Med Biol. 2010;686:211-22. doi: 10.1007/978-90-481-9485-8-13.
45. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. A comparative study of European rare disease and orphan drug markets. Health Policy. 2010;97(2-3):173-9.
46. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Issues surrounding orphan disease and orphan drug policies in Europe. Appl Health Econ Health Policy. 2010;8(5):343-50.
47. Coyle D, Cheung MC, Evans GA. Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria. Med Decis Making. 2014. doi: 10.1177/0272989x14539731.
48. Heemstra HE. Variations in access and use of orphan drugs among EU member states. EJHP Practice. 2010;16(4):25-7.
49. Kanters TA, Steenhoek A, Hakkaart L. Orphan drugs expenditure in the Netherlands in the period 2006-2012. Orphanet J Rare Dis. 2014;9:154. doi: 10.1186/s13023-014-0154-0.
50. Hutchings A, Schey C, Dutton R, Achana F, Antonov K. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020. Orphanet J Rare Dis. 2014;9:22. doi: 10.1186/1750-1172-9-22.
51. Rollet P, Lemoine A, Dunoyer M. Sustainable rare diseases business and drug access: no time for misconceptions. Orphanet J Rare Dis. 2013;8(1):1-9.
52. Picavet E, Cassiman D, Simoens S. Reimbursement of orphan drugs in Belgium: what (else) matters? Orphanet J Rare Dis. 2014;9(1):139. doi: 10.1186/s13023-014-0139-z.
53. Winquist E, Coyle D, Clarke JTR, Evans GA, Seager C, Chan W, et al. Application of a policy framework for the public funding of drugs for rare diseases. J Gen Intern Med. 2014;29(SUPPL. 3):S774-S9.
54. Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ. 2010;13(2):295-301. doi: 10.3111/13696998.2010.491427.
55. Denis A, Mergaert L, Fostier C, Cleemput I, Hulstaert F, Simoens S. Critical assessment of Belgian reimbursement dossiers of orphan drugs. Pharmacoeconomics. 2011;29(10):883-93.
56. Koçkaya G, Wertheimer AI, Kilic P, Tanyeri P, Mert Vural I, Akbulat A, et al. An overview of the orphan medicines market in Turkey. Value in Health Reg Issues. 2014;4(1):47-52.
57. Morgane M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):23-9. doi: 10.1586/erp.11.95.
58. Vegter S, Rozenbaum MH, Postema R, Tolley K, Postma MJ. Review of regulatory recommendations for orphan drug submissions in the netherlands and scotland: focus on the underlying pharmacoeconomic evaluations. Clin Ther. 2010;32(9):1651-61.
59. Tambuyzer E. Rare diseases, orphan drugs and their regulation: Questions and misconceptions. Nat Rev Drug Discov. 2010;9(12):921-9.
60. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23(1):36-42.
61. Desser AS, Olsen JA, Grepperud S. Eliciting preferences for prioritizing treatment of rare diseases: the role of opportunity costs and framing effects. Pharmacoeconomics. 2013;31(11):1051-61.
62. Hughes D. Rationing of drugs for rare diseases. Pharmacoeconomics. 2006;24(4):315-6.
63. McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: Should we value rarity? Br Med J. 2005;331(7523):1016-9.
64. Hughes D. Orphan drugs revisited: Author's response [4]. QJM. 2006;99(5):350-1.
65. Hyry HI, Stern AD, Cox TM, Roos JC. Limits on use of health economic assessments for rare diseases. QJM. 2014;107(3):241-5. doi: 10.1093/qjmed/hcu016.
66. Burls A, Austin D, Moore D. Commissioning for rare diseases: view from the frontline. Br Med J. 2005;331(7523):1019-21.
67. Nice Citizens Council Report - Ultra Orphan Drugs. National Institute for Clinical Excellence, London. 2004. https://www.nice.org.uk/Media/Default/Get-involved/Citizens-Council/Reports/CCReport04UltraOrphanDrugs.pdf. Accessed 5 Oct 2015.
68. Desser AS. Prioritizing treatment of rare diseases: a survey of preferences of Norwegian doctors. Soc Sci Med. 2013;94:56-62.
69. Dragojlovic N, Rizzardo S, Bansback N, Mitton C, Marra CA, Lynd LD. Challenges in measuring the societal value of orphan drugs: insights from a canadian stated preference survey. Patient. 2015;8(1):93-101. doi: 10.1007/s40271-014-0109-5.
70. Desser AS, Gyrd-Hansen D, Olsen JA, Grepperud S, Kristiansen IS. Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. BMJ. 2010;341:c4715. doi: 10.1136/bmj.c4715.
71. Cheng MM, Ramsey SD, Devine EB, Garrison LP, Bresnahan BW, Veenstra DL. Systematic review of comparative effectiveness data for oncology orphan drugs. Am J Manag Care. 2012;18(1):47-62.
72. McCabe C, Tsuchiya A, Claxton K, Raftery J. Orphan drugs revisited. QJM. 2006;99(5):341-5.
73. Cost effectiveness and strategic planning (WHO-CHOICE) WHO. http://www.who.int/choice/costs/CER-levels/en/. Accessed 20.10.2015.
74. Kaló Z, Gheorghe A, Huic M, Csanádi M, Kristensen FB. HTA Implementation Roadmap in Central and Eastern European Countries. Health Econ. 2016;25 Suppl 1:179-92. doi: 10.1002/hec.3298.
75. Fishman JC, Skrepnek GH. Pharmacoeconomic analyses of treatments for rare disease. Pharm Policy Law. 2012;14(1):51-67.
76. Sheehan M. Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness. BMJ. 2005;331(7525):1144-5.
77. London AJ. How should we model rare disease allocation decisions? Hastings Cent Rep. 2012;42(1):3.
78. Kolasa K, Zwolinski KM, Kalo Z, Hermanowski T. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs. Orphanet J Rare Dis. 2016;11:23. doi: 10.1186/s13023-016-0388-0.
79. Szegedi M, Molnar MJ, Boncz I, Kosztolanyi G. Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary. Orv Hetil. 2014;155(44):1735-41. doi: 10.1556/oh.2014.30031.
80. Drummond M, Augustovski F, Kalo Z, Yang BM, Pichon-Riviere A, Bae EY et al. Challenges faced in transferring economic evaluations to middle income countries. Int J Technol Assess Health Care. 2015;31(6):442-8. doi: 10.1017/s0266462315000604.
81. Morrison V, Fargher E, Parveen S, Plumpton C. Determinants of patient adherence to antihypertensive medication: a multi-national cross-sectional survey. Ascertaining Barriers for Compliance: policies for safe, effective and cost-effective use of medicines in Europe - Final Report. 2012. p. 78-103.
82. Kalo Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13(6):735-41. doi: 10.1586/14737167.2013.847367.
83. O'Mahony B, Noone D, Giangrande PL, Prihodova L. Haemophilia care in Europe - a survey of 35 countries. Haemophilia. 2013;19(4):e239-47. doi: 10.1111/hae.12125.
84. EURORDIS. Improving patient access to orphan drugs in Europe EURORDIS. 2009. http://www.eurordis.org/content/improving-patient-access-orphan-drugs-europe. Accessed 29.04.2016.
85. EUCERD. EUCERD Recommendation for a CAVOMP Information Flow. 2012. http://www.eurordis.org/sites/default/files/cavomp.pdf. Accessed 20.04.2016.
86. MoCA-OMP. Process on Corporate Social Responsibility in the Field of Pharmaceuticals - Platform on Access to Medicines in Europe, Working Group on Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA-OMP). 2013. http://ec.europa.eu/DocsRoom/documents/7631/attachments/1/translations/en/renditions/pdf. Accessed 18.04.2016.
87. Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, Hughes DA, International Society for Pharmacoeconomics and Outcomes Research Rare Disease Special Interest Group. Rare disease terminology and definitions-a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18(6):906-14.
88. Kristensen FB, Mäkelä M, Neikter SA, Rehnqvist N, Håheim LL, Mørland B, Milne R, Nielsen CP, Busse R, Lee-Robin SH, Wild C, Espallargues M, Chamova J, European network for Health Technology Assessment (EUnetHTA). European network for health technology assessment, EUnetHTA: planning, development, and implementation of a sustainable European network for health technology assessment. Int J Technol Assess Health Care. 2009;25 Suppl 2:107-16.
89. Davies JE, Neidle S, Taylor DG. Developing and paying for medicines for orphan indications in oncology: Utilitarian regulation vs equitable care. Br J Cancer. 2012;106(1):14-7.
90. Simoens S, Cassiman D, Dooms M, Picavet E. Orphan drugs for rare diseases: Is it time to revisit their special market access status? Drugs. 2012;72(11):1437-43.
91. What type of evidence is currently being considered in the development of clinical practice guidelines for rare diseases? Institute for Quality and Efficiency in Health Care: Executive Summaries. 2011. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0065182/pdf/PubMedHealth-PMH0065182.pdf. Accessed 2 October 2015.
92. Mentzakis E, Stefanowska P, Hurley J. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study. Health Econ Policy Law. 2011;6(3):405-33.
93. Picavet E, Dooms M, Cassiman D, Simoens S. Orphan drugs for rare diseases: grounds for special status. Drug Dev Res. 2012;73(3):115-9.
94. European policies on orphan diseases and drugs stimulate drug development, but could be improved. Drugs Ther Perspect. 2011;27(5):24-6. doi: 10.2165/11601550-000000000-00000.
95. Hogerzeil HV. Rare diseases and essential medicines: Global perspective. Int J Pharm Med. 2005;19(5-6):285-8.
96. Pinxten W, Denier Y, Dooms M, Cassiman JJ, Dierickx K. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation. J Med Ethics. 2012;38(3):148-53.
97. Kinney J. Health disparities: exploring the ethics of orphan drugs. Am J Health Syst Pharm. 2014;71(9):692-3.
98. Largent EA, Pearson SD. Which orphans will find a home? The rule of rescue in resource allocation for rare diseases. Hastings Cent Rep. 2012;42(1):27-34.